ADORA2A and myeloid sarcoma: Collectively, these findings define the CP niche as one of the primary sites for the A2AR antagonist to confer protection against EAE pathology. Thus, pharmacological targeting of the CP-A2AR represents a novel treatment strategy for MS by controlling immune cell trafficking across the CP.